Fate Therapeutics (FATE) News Today $2.02 -0.06 (-2.88%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Wedbush Equities Analysts Reduce Earnings Estimates for FATENovember 16 at 2:19 AM | americanbankingnews.comFY2024 EPS Estimate for Fate Therapeutics Lowered by AnalystFate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Analysts at Wedbush reduced their FY2024 earnings per share (EPS) estimates for shares of Fate Therapeutics in a research report issued to clients and investors on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that thNovember 15 at 7:14 AM | marketbeat.comFate Therapeutics Unveils Q3 2024 Financial HighlightsNovember 14 at 9:14 PM | markets.businessinsider.comOptimistic Outlook for Fate Therapeutics Amid Promising Cell Therapy DevelopmentsNovember 14 at 11:09 AM | markets.businessinsider.comCautious Hold Rating for Fate Therapeutics Amidst Clinical Uncertainties and Financial StabilityNovember 14 at 11:09 AM | markets.businessinsider.comFate Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 14 at 11:09 AM | finance.yahoo.comAnalysts Are Neutral on These Healthcare Stocks: Fate Therapeutics (FATE), BridgeBio Pharma (BBIO)November 13, 2024 | markets.businessinsider.comConservative Hold Rating for Fate Therapeutics Amid Early Pipeline Development and Unclear Competitive EdgeNovember 13, 2024 | markets.businessinsider.comFate Therapeutics (FATE) Receives a Buy from BarclaysNovember 13, 2024 | markets.businessinsider.comFate Therapeutics (NASDAQ:FATE) Given Hold Rating at Needham & Company LLCNeedham & Company LLC reiterated a "hold" rating on shares of Fate Therapeutics in a report on Wednesday.November 13, 2024 | marketbeat.comFate Therapeutics Reports Third Quarter 2024 Financial Results and Business UpdatesNovember 12, 2024 | globenewswire.comFate Therapeutics, Inc. (NASDAQ:FATE) Receives $6.90 Consensus Price Target from BrokeragesNovember 11, 2024 | americanbankingnews.comFate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual MeetingNovember 9, 2024 | globenewswire.comFate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual MeetingNovember 8, 2024 | globenewswire.comFate Therapeutics (NASDAQ:FATE) Stock Crosses Below 200 Day Moving Average - Here's WhyFate Therapeutics (NASDAQ:FATE) Share Price Passes Below Two Hundred Day Moving Average - Time to Sell?November 8, 2024 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by BrokeragesFate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) has received an average rating of "Hold" from the twelve analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and fourNovember 8, 2024 | marketbeat.comFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)November 4, 2024 | globenewswire.comFate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Rating of "Hold" from AnalystsShares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) have been given an average rating of "Hold" by the twelve analysts that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendaOctober 14, 2024 | marketbeat.comDimensional Fund Advisors LP Grows Position in Fate Therapeutics, Inc. (NASDAQ:FATE)Dimensional Fund Advisors LP raised its stake in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 100.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,130,280 shares ofOctober 9, 2024 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comRenaissance Technologies LLC Takes $1.80 Million Position in Fate Therapeutics, Inc. (NASDAQ:FATE)Renaissance Technologies LLC acquired a new position in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 548,544 shares of the biopharmaceutical company'October 4, 2024 | marketbeat.comFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)October 2, 2024 | globenewswire.comPerceptive Advisors LLC Invests $1.13 Million in Fate Therapeutics, Inc. (NASDAQ:FATE)Perceptive Advisors LLC acquired a new position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 345,575 shares ofSeptember 30, 2024 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Shares Acquired by Deerfield Management Company L.P. Series CDeerfield Management Company L.P. Series C lifted its stake in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 62.3% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,555,871 shares of the biopSeptember 26, 2024 | marketbeat.com‘Fate Is Woven’ Teaser Airs On 9/23 WWE RAWSeptember 24, 2024 | yahoo.comA Year Ago Kevin McCarthy Was Booted as House Speaker. Mike Johnson Is Trying to Avoid That FateSeptember 24, 2024 | usnews.comIntegral Health Asset Management LLC Acquires 650,000 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)Integral Health Asset Management LLC grew its holdings in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 325.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 850,000 shares of theSeptember 23, 2024 | marketbeat.comTop 10 Funniest Rare Items in FateSeptember 21, 2024 | msn.comFate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of "Hold" by BrokeragesShares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) have earned an average rating of "Hold" from the twelve brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a hoSeptember 19, 2024 | marketbeat.comTop 10 Rare Gemstones in FateSeptember 18, 2024 | msn.comE Fund Management Co. Ltd. Increases Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)E Fund Management Co. Ltd. increased its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 930.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 355,225 shares of the biopharSeptember 18, 2024 | marketbeat.comCrunchyroll Announces Stream of Fate/stay Franchise's New Anime Following U.S. World PremiereSeptember 18, 2024 | msn.comBruce & Co. Inc. Has $984,000 Position in Fate Therapeutics, Inc. (NASDAQ:FATE)Bruce & Co. Inc. grew its holdings in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 109.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 300,000 shares of the biopharmaceutical company'sSeptember 16, 2024 | marketbeat.comFate Trigger: The Novita is a new battle royale that mixes Fortnite, Valorant, and animeSeptember 15, 2024 | msn.comFate Therapeutics to Present at 2024 Cantor Global Healthcare ConferenceSeptember 12, 2024 | globenewswire.comFate Therapeutics, Inc. (NASDAQ:FATE) Stake Lifted by Acadian Asset Management LLCAcadian Asset Management LLC boosted its stake in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 17.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,008,862 shares of the biopharmaceutical company's sSeptember 12, 2024 | marketbeat.comFate Therapeutics IncAugust 27, 2024 | morningstar.comAnalysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT) and Fate Therapeutics (FATE)August 22, 2024 | markets.businessinsider.comFate Therapeutics: Hold Rating Amid Financial Stability and Upcoming MilestonesAugust 22, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Neutral" Rating for Fate Therapeutics (NASDAQ:FATE)HC Wainwright reaffirmed a "neutral" rating and issued a $5.00 price objective on shares of Fate Therapeutics in a report on Thursday.August 22, 2024 | marketbeat.comFY2024 EPS Estimates for Fate Therapeutics, Inc. Increased by Cantor Fitzgerald (NASDAQ:FATE)Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Stock analysts at Cantor Fitzgerald upped their FY2024 EPS estimates for Fate Therapeutics in a research note issued on Tuesday, August 20th. Cantor Fitzgerald analyst L. Watsek now forecasts that the biopharmaceutical company will post earninAugust 22, 2024 | marketbeat.comCidara Therapeutics, Inc.: Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business OfficerAugust 20, 2024 | finanznachrichten.deFate Therapeutics’ Promising Outlook: Buy Rating on Innovative Cell Therapy Programs FT819 and FT522August 20, 2024 | markets.businessinsider.comOff the Grid: Sally breaks down USA TODAY's daily crossword puzzle, Twist of FateAugust 19, 2024 | msn.comFate Therapeutics (FATE) Gets a Hold from Stifel NicolausAugust 19, 2024 | markets.businessinsider.comFate Therapeutics maintains target price with Overweight ratingAugust 16, 2024 | investing.comAkebia Therapeutics: Generics Competition Means Rough Weather AheadAugust 16, 2024 | seekingalpha.comFate Therapeutics: Hold Rating Amidst Steady Q2 Financials and Clinical ProgressAugust 16, 2024 | markets.businessinsider.comWedbush Comments on Fate Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:FATE)Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Stock analysts at Wedbush lifted their Q3 2024 earnings per share (EPS) estimates for shares of Fate Therapeutics in a report issued on Tuesday, August 13th. Wedbush analyst D. Nierengarten now forecasts that the biopharmaceutical company willAugust 16, 2024 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Announces Quarterly Earnings Results, Beats Expectations By $0.14 EPSFate Therapeutics (NASDAQ:FATE - Get Free Report) posted its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating analysts' consensus estimates of ($0.47) by $0.14. The firm had revenue of $6.77 million during the quarter, compared to the consensus estimate of $1.47 million. Fate Therapeutics had a negative return on equity of 46.49% and a negative net margin of 2,933.79%.August 15, 2024 | marketbeat.com Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Stocks that could triple in a week (Ad)Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here. Click here to pay just $5 for a full year of Stealth Trades FATE Media Mentions By Week FATE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FATE News Sentiment▼0.140.56▲Average Medical News Sentiment FATE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FATE Articles This Week▼194▲FATE Articles Average Week Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Adaptimmune Therapeutics News Cellectis News bluebird bio News Atara Biotherapeutics News Allogene Therapeutics News Collegium Pharmaceutical News 89bio News CARGO Therapeutics News Phathom Pharmaceuticals News Mesoblast News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FATE) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FATE Stock Alerts